Suven Life Sciences Ltd Stock Price Today (NSE: SUVEN)

Suven Life Sciences Ltd

307.20+7.95 (+2.66%)
Market Closed

Fundamental Score

...

Suven Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Suven Life Sciences Ltd share price today is 307.20, up +2.66% on NSE/BSE as of 3 August 2026. Suven Life Sciences Ltd (SUVEN) is a Mid-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 10.07K (Cr). The 52-week high for SUVEN share price is 371.00 and the 52-week low is 124.11. The company has a Return on Equity (ROE) of -78.80% and a debt-to-equity ratio of 0.03.

Suven Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
371.00
Low
272.20
Volume
19.6L
Change
+12.14%

Suven Life Sciences Ltd share price chart: 12.14% return over the past month. 52-week high ₹371.00, 52-week low ₹124.11.

Suven Life Sciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
302.00310.00297.60307.104.50L (Cr)
297.00314.80294.20313.3510.98L (Cr)
311.65313.50290.50294.1511.04L (Cr)
319.00319.85310.05311.655.11L (Cr)
337.95344.95331.55340.455.20L (Cr)
325.90344.25323.40338.5011.19L (Cr)
341.00342.35321.50325.9011.06L (Cr)
357.00357.00335.80341.1510.53L (Cr)
361.35365.60345.00348.207.63L (Cr)
360.00371.00353.80359.5512.75L (Cr)

Suven Life Sciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
280.65371.00272.20307.10+9.42%
297.95297.95230.60280.65-5.81%
211.84294.88200.00279.34+31.86%
139.50229.69135.50211.88+51.89%
140.00148.00124.11131.70-5.93%
139.90176.02131.63146.07+4.41%
166.50178.50125.45132.81-20.23%
172.50183.80160.20166.27-3.61%
198.37207.01166.55172.14-13.22%
204.21216.79186.00197.55-3.26%
209.00235.67200.00204.21-2.29%
269.00273.00208.00213.95-20.46%

Returns & Performance

Poor

Return on Equity (ROE)

-78.80%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-76.92%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-1624.61%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Suven Life Sciences Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

39.78x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

70.15%

% shares held by company founders/management

Poor

FII Holding

0.91%

% shares held by foreign institutional investors

Poor

DII Holding

4.62%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-3.78%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

3.40%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-12.01%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.03x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-1726.13x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-877.48 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Suven Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SUVEN across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Conservative Debt Levels (D/E: 0.03)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Balanced Promoter Holding (70.15%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (-78.80%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-76.92%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-1624.61%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Limited Growth History (-12.01% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-1726.13x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-877.48 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 5.53%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Suven Life Sciences Ltd vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Suven Life Sciences Ltd with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
11.4/100
307
₹10067.84
-78.80%
Poor
-76.92%
Poor
0.0
Excellent
-12.01%
Poor
0.00%
35.4/100
386
₹16982.38
47.1
Average
7.71%
Poor
9.91%
Poor
0.0
Excellent
-0.98%
Poor
9.45%
Good
0.30%
57/100
515
₹12302.12
29.7
Average
14.41%
Average
18.82%
Good
0.1
Excellent
23.02%
Excellent
29.44%
Excellent
0.39%
63.6/100
609
₹2555.98
32.4
Average
18.87%
Good
25.23%
Excellent
0.0
Excellent
29.96%
Excellent
14.27%
Good
0.35%
31.2/100
21
₹304.13
71.4
Average
16.53%
Good
18.51%
Good
0.0
Excellent
15.08%
Excellent
-41.25%
Poor
0.00%
56.9/100
69
₹199.32
77.9
Average
8.00%
Poor
9.98%
Poor
0.1
Excellent
22.72%
Excellent
151.69%
Excellent
0.00%
28.9/100
58
₹147.94
26.8
Average
1.66%
Poor
5.56%
Poor
3.1
Poor
16.32%
Excellent
3.33%
Average
0.00%
24.6/100
16
₹24.53
19.5
Average
3.35%
Poor
5.21%
Poor
0.2
Excellent
-6.68%
Poor
-3.19%
Poor
0.00%
23.9/100
24
₹17.99
163.6
Average
0.70%
Poor
1.19%
Poor
1.8
Average
-24.21%
Poor
-28.62%
Poor
0.00%

Suven Life Sciences Ltd Quarterly Performance

Latest quarterly metrics for SUVEN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

3.40%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-3.78%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-12.01%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Suven Life Sciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SUVEN — calculated from daily price history

48RSI 14
Neutral — RSI 48

Momentum is balanced — neither overbought nor oversold.

SMA 50
286
▲ Price above SMA 50 — Short-term bullish
SMA 200
200
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1828K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Suven Life Sciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Suven Life Sciences Ltd (SUVEN) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Suven Life Sciences Ltd

About SUVEN (Suven Life Sciences Ltd)

Suven Life Sciences Ltd is a pioneering force in the healthcare sector, operating at the intersection of cutting-edge research, advanced analytics, and transformative technology. T...he company dedicates its efforts to unraveling the complexities of neurodegenerative diseases, particularly those affecting the central nervous system. Through rigorous scientific investigation and innovative drug discovery processes, Suven aims to identify and develop novel therapeutic interventions with the potential to significantly improve the lives of patients suffering from conditions like Alzheimer's disease and other neuropsychiatric disorders. Their commitment extends beyond the laboratory, as they actively engage in clinical trials and seek to translate scientific breakthroughs into tangible treatments accessible to patients worldwide. Suven’s approach leverages a blend of sophisticated analytical tools and a deep understanding of disease mechanisms. They meticulously analyze vast datasets to identify potential drug targets and optimize the development of new chemical entities. This data-driven approach, combined with a strong emphasis on intellectual property and strategic partnerships, allows Suven to navigate the challenging landscape of pharmaceutical development with agility and precision. Their research focuses on identifying innovative solutions that address unmet medical needs, striving to provide effective treatments that can slow down disease progression, alleviate symptoms, and ultimately enhance the quality of life for individuals and families affected by debilitating neurological conditions. Driven by a vision of a healthier future, Suven Life Sciences is committed to fostering a culture of scientific excellence and innovation. Their multifaceted operations encompass drug discovery, clinical development, and strategic commercialization planning, all while maintaining a focus on ethical research practices and patient-centered care. By embracing emerging technologies and continually refining their analytical capabilities, Suven positions itself as a dynamic player in the global healthcare arena, working tirelessly to advance the frontiers of neurological disease treatment and contribute to a more hopeful outlook for those affected by these challenging conditions.

Company Details

Symbol:SUVEN
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Mr. Venkateswarlu Jasti M.Pharm. M.S.
CEO, MD & Executive Chairman
Dr. N. V. S. Ramakrishna M.Sc, Ph.D.
President & Chief Scientific Officer
Ms. Sudharani Jasti B.Sc.
Whole-Time Director

SUVEN Share Price: Frequently Asked Questions

What is the current share price of Suven Life Sciences Ltd?

Suven Life Sciences Ltd (SUVEN) trades at ₹307.20 on NSE and BSE. Market cap ₹10.07K (Cr). Educational data only.

What is the P/E ratio of Suven Life Sciences Ltd?

Suven Life Sciences Ltd has a P/E of N/Ax vs industry average 39.78x.

What is the Bull Run score for Suven Life Sciences Ltd?

Suven Life Sciences Ltd has a Bull Run score of 11.4/100 based on 25+ financial parameters.

Does Suven Life Sciences Ltd pay dividends?

Suven Life Sciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Suven Life Sciences Ltd?

Suven Life Sciences Ltd has ROE of -78.80%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Suven Life Sciences Ltd?

Suven Life Sciences Ltd has debt-to-equity of 0.03.

Is Suven Life Sciences Ltd a good investment?

Bull Run gives Suven Life Sciences Ltd a score of 11.4/100. This is not investment advice — consult a SEBI-registered advisor.